Patent ID: 8926979
Filing Date: 2015-01-06
Classification: A61K,A61P,C07K,C12Q

Abstract:
1. A method for treating a human patient for a cancer or pre-malignant condition that is associated with cells expressing both CD40 and CD20 and which is refractory to treatment with rituximab (Rituxan®), said method comprising: a) genotyping a biological sample obtained from said human patient to determine said human patient's FcγRIIIa-158 genotype (V/V, V/F, or F/F); b) identifying said human patient as being heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F), and c) administering to said human patient identified as being heterozygous or homozygous for FcγRIIIa-158F (genotype V/F or F/F) a therapeutically or prophylactically effective amount of an anti-CD40 antibody that mediates antibody-dependent cellular cytotoxicity (ADCC) against CD40-expressing cells,